XOMA ROYALTY CORPORATION(NASDAQ:XOMA) stock News

XOMA Latest News, Press Relases and Analysis

All

Press Releases

5 days ago - By: ESSA Pharma Inc. - Mentions: EPIX

ESSA Pharma Inc. Amends Agreement with XenoTherapeutics

7 days ago - By: XOMA Royalty Corporation

XOMA Royalty Declares Quarterly Preferred Stock Dividends

7 days ago - By: XOMA Royalty Corporation

XOMA Royalty Declares Quarterly Preferred Stock Dividends

12 days ago - By: XOMA Royalty Corporation

XOMA Royalty Announces Closing of Tender Offer for HilleVax, Inc.

12 days ago - By: XOMA Royalty Corporation - Mentions: HLVX

XOMA Royalty Announces Closing of Tender Offer for HilleVax, Inc.

a month ago - By: Stocktwits - Mentions: MURA

Mural Oncology To Be Acquired By Xoma Royalty

a month ago - By: Zacks Investment Research

Wall Street Analysts Predict an 86.05% Upside in XOMA Royalty (XOMA): Here's What You Should Know

a month ago - By: XOMA Royalty Corporation

XOMA Royalty to Present at H.C. Wainwright 27th Annual Global Investment Conference

a month ago - By: XOMA Royalty Corporation

XOMA Royalty to Present at H.C. Wainwright 27th Annual Global Investment Conference

a month ago - By: Zacks Investment Research

Here's Why XOMA Royalty (XOMA) Is a Great 'Buy the Bottom' Stock Now

a month ago - By: XOMA Royalty Corporation

Mural Oncology Announces Entry into Agreement to be Acquired by XRA 5 Corp., a wholly owned subsidiary of XOMA Royalty for between $2.035 and $2.24 in Cash per Share

a month ago - By: Kahn Swick & Foti, LLC - Mentions: HLVX

HILLEVAX INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of HilleVax, Inc. - HLVX

a month ago - By: Zacks Investment Research

How Much Upside is Left in XOMA Royalty (XOMA)? Wall Street Analysts Think 106.15%

2 months ago - By: Zacks Investment Research - Mentions: HOWL

XOMA Royalty (XOMA) Q2 Earnings and Revenues Surpass Estimates

2 months ago - By: The Motley Fool

XOMA Revenue Jumps 39% in Fiscal Q2

2 months ago - By: Rowley Law PLLC - Mentions: HLVX

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of HilleVax, Inc.

4 months ago - By: Benzinga

XOMA Royalty Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)

2 months ago - By: XOMA Royalty Corporation

XOMA Royalty Reports Second Quarter and Year to Date 2025 Financial Results and Highlights Recent Business Achievements

2 months ago - By: XOMA Royalty Corporation

XOMA Royalty Reports Second Quarter and Year to Date 2025 Financial Results and Highlights Recent Business Achievements

2 months ago - By: XOMA Royalty Corporation

XOMA Royalty Announces Closing of Tender Offer for Turnstone Biologics

2 months ago - By: XOMA Royalty Corporation - Mentions: TSBX

XOMA Royalty Announces Closing of Tender Offer for Turnstone Biologics

2 months ago - By: Zacks Investment Research - Mentions: PTCT

PTC Therapeutics (PTCT) Reports Q2 Loss, Beats Revenue Estimates

2 months ago - By: Zacks Investment Research - Mentions: NVAX

Novavax (NVAX) Q2 Earnings and Revenues Top Estimates

2 months ago - By: Brodsky & Smith LLC - Mentions: HLVX SCS LVTX RKDA ...

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: HilleVax, Inc. (Nasdaq – HLVX), Steelcase Inc. (NYSE – SCS), LAVA Therapeutics N.V. (Nasdaq – LVTX), Arcadia Biosciences, Inc. (Nasdaq – RKDA)

2 months ago - By: XOMA Royalty Corporation; LAVA Therapeutics N.V.

XOMA Royalty Enters into Agreement to Acquire LAVA Therapeutics for Between $1.16 and $1.24 Per Share in Cash, Plus a Contingent Value Right

2 months ago - By: XOMA Royalty Corporation; LAVA Therapeutics N.V. - Mentions: LVTX

XOMA Royalty Enters into Agreement to Acquire LAVA Therapeutics for Between $1.16 and $1.24 Per Share in Cash, Plus a Contingent Value Right

2 months ago - By: XOMA Royalty Corporation

HilleVax Enters into a Definitive Agreement to be Acquired by XOMA Royalty for $1.95 in Cash per Share Plus a Contingent Value Right

2 months ago - By: XOMA Royalty Corporation - Mentions: HLVX

HilleVax Enters into a Definitive Agreement to be Acquired by XOMA Royalty for $1.95 in Cash per Share Plus a Contingent Value Right

3 months ago - By: ESSA Pharma Inc - Mentions: EPIX

ESSA Pharma Inc. Announces Definitive Agreement to be Acquired by XenoTherapeutics, Inc., Backed by XOMA Royalty Corporation in All-Cash Transaction

3 months ago - By: Brodsky & Smith LLC - Mentions: CARM OCGN GNTY GBCI ...

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Carisma Therapeutics Inc. (Nasdaq - CARM), Guaranty Bancshares, Inc. (NYSE - GNTY), MRC Global Inc. (NYSE - MRC), Turnstone Biologics Corp. (Nasdaq - TSBX)

3 months ago - By: Stocktwits - Mentions: TSBX TSLA GM

Turnstone Biologics To Merge With Biotech Royalty Aggregator XOMA, But Retail Sentiment Slumps

3 months ago - By: XOMA Royalty Corporation; Turnstone Biologics Corp.

Turnstone Biologics Corp. Enters into Agreement to be Acquired by XOMA Royalty Corporation for $0.34 in Cash Per Share Plus a Contingent Value Right

3 months ago - By: XOMA Royalty Corporation; Turnstone Biologics Corp. - Mentions: TSBX

Turnstone Biologics Corp. Enters into Agreement to be Acquired by XOMA Royalty Corporation for $0.34 in Cash Per Share Plus a Contingent Value Right

3 months ago - By: XOMA Royalty Corporation

XOMA Royalty Declares Quarterly Preferred Stock Dividends

3 months ago - By: XOMA Royalty Corporation

XOMA Royalty Declares Quarterly Preferred Stock Dividends

4 months ago - By: XOMA Royalty Corporation; BioInvent

XOMA ROYALTY CORPORATION (XOMA) Stock News

XOMA Latest News, Press Relases and Analysis

ESSA Pharma Inc. Amends Agreement with XenoTherapeutics

XOMA Royalty Declares Quarterly Preferred Stock Dividends

XOMA Royalty Declares Quarterly Preferred Stock Dividends

XOMA Royalty Announces Closing of Tender Offer for HilleVax, Inc.

XOMA Royalty Announces Closing of Tender Offer for HilleVax, Inc.

Mural Oncology To Be Acquired By Xoma Royalty

Wall Street Analysts Predict an 86.05% Upside in XOMA Royalty (XOMA): Here's What You Should Know

XOMA Royalty to Present at H.C. Wainwright 27th Annual Global Investment Conference

XOMA Royalty to Present at H.C. Wainwright 27th Annual Global Investment Conference

Here's Why XOMA Royalty (XOMA) Is a Great 'Buy the Bottom' Stock Now

Mural Oncology Announces Entry into Agreement to be Acquired by XRA 5 Corp., a wholly owned subsidiary of XOMA Royalty for between $2.035 and $2.24 in Cash per Share

HILLEVAX INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of HilleVax, Inc. - HLVX

How Much Upside is Left in XOMA Royalty (XOMA)? Wall Street Analysts Think 106.15%

XOMA Royalty (XOMA) Q2 Earnings and Revenues Surpass Estimates

XOMA Revenue Jumps 39% in Fiscal Q2

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of HilleVax, Inc.

XOMA Royalty Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)

XOMA Royalty Reports Second Quarter and Year to Date 2025 Financial Results and Highlights Recent Business Achievements

XOMA Royalty Reports Second Quarter and Year to Date 2025 Financial Results and Highlights Recent Business Achievements

XOMA Royalty Announces Closing of Tender Offer for Turnstone Biologics

XOMA Royalty Announces Closing of Tender Offer for Turnstone Biologics

PTC Therapeutics (PTCT) Reports Q2 Loss, Beats Revenue Estimates

Novavax (NVAX) Q2 Earnings and Revenues Top Estimates

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: HilleVax, Inc. (Nasdaq – HLVX), Steelcase Inc. (NYSE – SCS), LAVA Therapeutics N.V. (Nasdaq – LVTX), Arcadia Biosciences, Inc. (Nasdaq – RKDA)

XOMA Royalty Enters into Agreement to Acquire LAVA Therapeutics for Between $1.16 and $1.24 Per Share in Cash, Plus a Contingent Value Right

XOMA Royalty Enters into Agreement to Acquire LAVA Therapeutics for Between $1.16 and $1.24 Per Share in Cash, Plus a Contingent Value Right

HilleVax Enters into a Definitive Agreement to be Acquired by XOMA Royalty for $1.95 in Cash per Share Plus a Contingent Value Right

HilleVax Enters into a Definitive Agreement to be Acquired by XOMA Royalty for $1.95 in Cash per Share Plus a Contingent Value Right

ESSA Pharma Inc. Announces Definitive Agreement to be Acquired by XenoTherapeutics, Inc., Backed by XOMA Royalty Corporation in All-Cash Transaction

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Carisma Therapeutics Inc. (Nasdaq - CARM), Guaranty Bancshares, Inc. (NYSE - GNTY), MRC Global Inc. (NYSE - MRC), Turnstone Biologics Corp. (Nasdaq - TSBX)

Turnstone Biologics To Merge With Biotech Royalty Aggregator XOMA, But Retail Sentiment Slumps

Turnstone Biologics Corp. Enters into Agreement to be Acquired by XOMA Royalty Corporation for $0.34 in Cash Per Share Plus a Contingent Value Right

Turnstone Biologics Corp. Enters into Agreement to be Acquired by XOMA Royalty Corporation for $0.34 in Cash Per Share Plus a Contingent Value Right

XOMA Royalty Declares Quarterly Preferred Stock Dividends

XOMA Royalty Declares Quarterly Preferred Stock Dividends

XOMA Royalty Purchases Mezagitamab Royalty and Milestone Rights Held by BioInvent International for up to USD $30 Million